Suicidality Risk of Chronic Pain Medications: History
View Latest Version
Please note this is an old version of this entry, which may differ significantly from the current revision.
Contributor:
Osman Syed
,
Predrag Jancic
,
Adam B. Fink
,
Nebojsa Nick Knezevic

Chronic pain is one of the main leading causes of disability in the world at present. A variety in the symptomatology, intensity and duration of this phenomenon has led to an ever-increasing demand of pharmacological treatment and relief. This demand for medication, ranging from well-known groups, such as antidepressants and benzodiazepines, to more novel drugs, was followed by a rise in safety concerns of such treatment options. 

  • drug safety
  • chronic pain
  • suicidality
  • opioids

1. Introduction

Current research estimates that 1.9 billion [1] individuals, and perhaps up to 30% [2] of the world’s population, suffers from chronic pain, which is a leading cause of disability globally [3]. Although defined as pain that persists or recurs for longer than 3 months, the taxonomy [4][5] of chronic pain conditions has evolved as the clinical and scientific understanding of the syndromes and diseases that comprise the condition have grown. At present, chronic pain is understood to be a form of chronic disease, underpinned by nociceptive, neuropathic, and nociplastic mechanisms that can overlap, and/or exist on a continuum [2].
The clinical symptomatology and syndromes [4] of chronic pain are as heterogenous as the pathophysiological process underpinning them and as varied as the pharmacological attempts to alleviate them. NSAIDs, opioids, benzodiazepines, gabapentinoids, multiple generations of antidepressants, steroids, and antipsychotic medications are all utilized as treatments [6]. Many of these medications, irrespective of the indication they are being used for, have well documented associations with self-harm, suicidality, and overdose [7][8][9][10]. This is further complicated by the association and comorbidity that exists between chronic pain and psychiatric conditions, such as depression [11], bipolar disorder [12], and schizophrenia [13], which are associated with self-harm, suicidality [14][15], and overdose [16] themselves. Additionally, these patients may only experience relief from their symptoms when using these medications, some of which have a well demonstrated addictive potential [17][18]. The totality of these factors renders this population vulnerable to both intentional and unintentional misuse if their medications naturally pose drug safety concerns.
Given this reality, therapeutic drug monitoring and pharmacovigilance are of the utmost importance in this patient population. In 2018, an interdisciplinary group of clinicians developed consensus-based recommendations regarding urine drug monitoring for chronic pain patients who are treated with opioids [19]. While the combination of urinary drug testing and immunoassays has been found to be appropriate in some studies [20], others concluded that immunoassays designed to detect opioids lack sensitivity and produce false negative results in up to 21% of cases [21]. These difficulties have been described in the case of therapeutic drug monitoring of benzodiazepines [22] as well. The current lack of effective, large-scale programs combined with the disruption in point of care monitoring during the pandemic has hindered progress in the realm of drug safety for chronic pain patients.

2. Socio-Demographic Characteristics

The socio-demographic parameters associated with a higher incidence of chronic pain are well known and established, with the main groups being age, sex, education, and marital status as well as socio-economic standing [1][23].
Age has consistently been a proven important risk factor for the development of chronic pain. Different studies suggest a wide range of prevalence of chronic pain amongst the elderly [24][25]. However, all are in agreement that the prevalence in the elderly is significantly higher compared to the younger population [26]. In addition, age has been reported as a specific risk factor for high-impact chronic pain [27].
Men are less likely to report the experience of chronic pain than women [28]. Similarly, women are more likely to seek diagnosis and treatment compared to men, which could in turn cause possible misleading statistics [29]. Women have a tendency to maladaptive coping strategies to pain, predisposing them to a possibility of developing chronic pain [30].
In women, schooling of 12 or more years was associated with a lower prevalence of chronic pain. In the same light, unemployed women show a higher prevalence of chronic pain compared to their employed counterparts. Marital status showed influence on both sexes, where an increased prevalence of chronic pain was noted in divorced or widowed women; yet, conversely, it decreased in single men compared to married, divorced, or widowed men [31].
Chronic pain is a well-established follower of lower socio-economic status and a poorer quality of life [32]. Those who are socio-economically deprived are not only more likely to experience chronic pain but also more likely to experience more severe pain and a greater level of pain-related disability [33]. It has also been shown that average pain intensity and pain-related disability was greater among African American than White respondents, and it decreased as wealth increased [33].
When it comes to suicidality and chronic pain, a review of the currently available literature reveals a myriad of research suggesting that suicidal ideation and suicidal attempts are more common in patients with chronic pain [34]. In addition to that, although assumed logical, patients with painful conditions are at a greater risk of suicide compared to patients with non-painful conditions [35].
Well-known risk factors for suicide in the general population include family history of suicide, previous attempts, comorbid depression, and female sex [36][37]; however, less is known for pain-specific risk factors.
Patients with simultaneous chronic pain and substance use disorders (SUDs) are a more complex topic. Physicians must focus on both chronic pain treatment as well as issues of medication safety and misuse. The data suggest that the current prevalence of SUDs amongst patients with chronic pain ranges from 3% to 48%, and that the lifetime SUD rate is somewhere between 16% and 74% [38]. Additionally, up to 11.5% of chronic pain patients that take opioids develop aberrant medication-related behaviors [39]. Other studies suggest that patients with chronic pain have a 2 to 3 times more likely chance of developing SUDs, compared to individuals without pain [40].

3 Pharmacological Treatment and Suicidality

3.1. Antidepressants

Overall, the use of antidepressants has increased in recent decades, with SSRIs leading this trend change since their discovery [41][42].
Though not the main indication, one of the treatment options for chronic pain have historically been antidepressants, with TCAs, SSRIs, and SNRIs being in the forefront of therapeutic options [43][44]. Patients with chronic pain are often treated for a prolonged period of time, usually with more than one type of medication [45], all of which have a vast side effect profile [46]. These factors, in combination with the psychological strain that these patients are exposed to [47], can lead to a mental state prone to suicidal thinking and ideation [48][49].
A variety of information currently exists on the topic of suicidality rates in correlation to antidepressant use, suggesting negative, positive and no correlation at all [50][51][52][53]. Randomized controlled trials (RCTs), baring the highest level of evidence, showed contradictory results, ranging from a significantly increased suicide risk while using antidepressants [54][55][56][57] to seemingly no change in such risk [58][59][60]. Nonetheless, the vast amount of literature showing that a relationship between these parameters might exist is worth mentioning.
Additionally, a 2009 study showed a highly age-dependent relationship between the use of antidepressants and suicidality. The research showed that young adults (aged 25 and younger) showed a higher suicidality rate on these medications, in adherence with findings in children and adolescents. Conversely, the use of antidepressants in adults (aged 25 and older) showed a protective factor against suicidality [60]. This discrepancy in response to the initiation of antidepressant treatment was later reproduced many times in the literature, further supporting the caution of prescribing these medication to children and younger adults [59][61]. However, it is of high importance to mention that, with an increased risk of suicide in untreated depression and no concrete proof of association between pharmacotherapy and changes suicidality, physicians are still urged to prescribe SSRIs to affected minors [50].
The time of onset of suicidality in relation to depression treatment is of key importance to understanding the possible connection between these states. Suicidal ideation and behavior can initially develop during depression treatment, expressed by the term treatment-emergent suicidal ideation (TESI). In the case of the already present suicidality that changes in intensity in reaction to treatment, the term treatment worsening of suicidal ideation (TWOSI) fits best [62][63]. Even though these terms have been linked to a poorer socio-economic status and genetic predisposition [63][64][65], the literature suggests that more research is needed to conclude such a relationship. Some nation-based studies have reproduced this correlation between the use of antidepressants and the onset of suicidal attempts [66][67].

3.2. Opioids

Among all the medication classes, opioids by far have received the most attention from the public in recent years. The socio-economic factors that are related to opioid use may directly contribute to the inherent risk of suicide with opioids. It has been theorized that the diminishment in the middle class and the general economic stress of workers has led to a use of opioids as a coping mechanism [68]. Furthermore, patients who are on opioid medications for extended periods of time have significantly increased risks of developing depression [69][70]. Both the relationship of opioid use with hardship, as well as the relationship between use and developing depression, seem likely candidates as the causes of opioid-related suicides.
The national center on health statics reported 80,311 overdose deaths involving opioids in 2021, about 75.4% of all lethal overdoses [71]. In October 2017, the opioid crisis was declared a public health emergency by the US government. The CDC reported that, in 2020, about 143 million prescriptions were written in the United States. This follows a general trend of declining prescriptions in the USA since 2012 [72]. While the general trend of declining opioid prescriptions may mean that certain communities are less encumbered by the societal burden of treating addiction, this effect is very clearly disproportionately applied across the USA. The CDC makes note of county-level trends that are extremely different than the nationwide averages, with certain counties reaching prescription rates (per 100 persons) up to nine times higher than the average (43.3 prescriptions per 100 persons) [72].
Prescription maps of the USA illustrate these trends, showing the dramatic patchwork of opioid prescription rates across the country. There are multiple theories that attempt to specifically define the risk factors that these areas share. Theories include income, race, and density of people (rural vs. urban development).
Regarding the effects of community structures and opioid misuse, a 2020 study investigated the relationship of income inequality and opioid prescription rates. The authors specifically investigated the variables of residential stability, defined as the level of connectedness between residents as assessed through people staying housed in the same place, as well as the variable of social isolation among individuals [73]. The authors were able to quantify these variables in a couple different ways. The Gini index was used as a measure of income inequality, residential stability was defined by the percentage of housing occupied by owners, and social isolation was indexed via the percentage of individuals who are disabled, the percentage of individuals who live alone, and those living in poverty. These variables were chosen as the demographic studied was those enrolled in Medicare, a program only available predominately to those above 65 years old, or with end-stage renal disease, amyotrophic lateral sclerosis, and those with severe disabilities. The authors found that high levels of income inequality are associated with low levels of residential stability and high levels of social isolation. Both variables in turn are related to more opioid prescriptions [73]. 
These conclusions across the last few paragraphs can be further related to the fact that income inequality has a correlation to depression and suicidality [74]. As these papers have shown, these inequities lead to more opioids being used, and there are likely going to be more completed suicides due to the relationship between access to a highly lethal suicide means and completion [75].
Looking beyond economic factors, sex differences are also quite profound in opioid-related suicide. In general, women attempt suicide at greater rates then men but die by suicide at significantly lower rates. In the context of opioid-related suicide, a large cross-sectional study found that women comprise 54% of lethal suicides with opioids [76]. This may be further contextualized by a higher incidence in concomitant mental health complaints among women being treated for opioid dependence [77], as well as women with opioid use disorder reporting usage to cope with negative emotions at a higher rate [78]. Of note, the overall intentional overdose rate for all medications decreased between 2012 and 2019, but increased among African American women [79]. This may be a reflection on the general change in demographics that comprises the opioid crisis in the USA.
It has been noted that there is a multifactorial incidence of lower access to psychiatry in minority populations [80][81][82], along with lower rates of naloxone access in minority populations. Therefore, it is possible that, among minority patients who intentionally overdose and are not revived, more suicides will be misclassified as unintentional deaths. In a population study of New York City opioid users, researchers found significant differences in naloxone use and training. The data showed that African American participants had a 0.4 odds ratio of naloxone training, African American people above 50 years of age had an odds ratio of 0.2, and African American women scored 0.27 compared to White women [83].

3.3. Gabapentinoids

The antiepileptics gabapentin and pregabalin are routinely used for the treatment of chronic neuropathic pain, and particularly diabetic neuropathy. While systematic reviews have validated their efficacy [84][85], experts are increasingly concerned about how ubiquitous their use has become [86]. By 2016, 64 million prescriptions were issued for gabapentin, making it the 10th most prescribed drug in the US market. This constitutes a rise of over 160% compared to 2012. Pregabalin sales generated USD 4.4 billion in 2106, more than doubling the sales value since 2012 [86]. This phenomenon was simultaneously occurring, with different magnitudes, across the world.
While the prevalence of conditions treated with these medications continues to increase, the opioid epidemic was equally, if not primarily, responsible for the increase in physicians prescribing gabapentinoids. Although the most common side effects of antiepileptics are well documented, dose-dependent, and reversible, the implication of gabapentinoids in drug misuse, self-harm, and suicidality has come into focus in recent years [8][86][87].
The association between antiepileptics and suicidality was described by multiple systematic reviews, prompting the FDA to issue a warning for 11 drugs, including gabapentin, in 2008. However, despite a growing body of literature on the topic, gabapentinoids are not considered controlled substances in Europe, Canada, Australia, or the United States at the federal level, although some states have begun to reclassify them individually [88].

3.4. Benzodiazepines

As previously mentioned, chronic pain patients are often polypharmacy patients, managing their symptoms with several treatment modalities. Especially in the United States, opioids take the main place in the treatment options for chronic pain [89]. However, the co-administration of benzodiazepines with opioids has been a prominent pain relief strategy for these patients [90][91][92], leading to concerns surrounding interaction and adverse-event amplification when used concomitantly [93][94][95][96][97][98]. A study found that patients with a co-prescription of opioids and benzodiazepines were more likely to be diagnosed with depression, PTSD, and bipolar disorder and were more likely to be prescribed additional medication, such as antidepressants [99].
The most common conditions that are primarily treated with benzodiazepines that are linked to possible suicidality are anxiety and insomnia [100][101]. Treating these conditions would lead to a logical decrease in suicidality, but what happens when the treatment option itself is a possible risk factor for suicide?
Various instances in the literature suggest a very strong association between the use of benzodiazepines and suicidality and suicide attempts. However, many of these studies fall under possible indication bias, linking the condition being treated to possible suicidality rather than the pharmacological treatment option itself [102][103][104][105][106]. Minimizing such biases, by using cohorts [107][108][109] and case–control studies [110], yielded similar positive correlations.
Benzodiazepines have been shown to increase aggression and impulsivity [111], both of which appear to be correlated to suicidal tendencies [112]. Recent studies showed a dose-dependent relationship with the incidence of suicidality, both in short- and long-term benzodiazepine use [104][108][113][114].

3.5. Other Medication Groups

3.5.1. Barbiturates

The combination acetaminophen/butalbital/caffeine pill uses the analgesic effects of acetaminophen with the barbiturate butalbital and caffeine for the treatment of tension headaches. A tension headache is a type of headache that causes pain in a band around the head bilaterally [115]. Out of all the medications studied in a 2019 paper, the combination acetaminophen/butalbital/caffeine pill was associated with the highest odds ratio of suicidal event increase after exposure, 1.68 (95 CI 1.16–2.44), with the paper able to study 1,154,666 patients that were prescribed this combination [116]. Headaches are one of the most common forms of pain, both acute and chronic. About 15.8% of the global population experiences headaches each day [117]. More specifically, a population study conducted in Denmark found a prevalence of chronic tension headaches at 2–3% [118].
The combination acetaminophen/butalbital/caffeine pill has been shown to be effective at anxiolysis in the tension headache population [119]. Although the pathogenesis of tension headaches has not been fully elucidated, there is likely a relationship with mental health diagnosis, with one study showing an 84% overlap in patients with tension headaches and psychiatric diagnosis [120]. This masking of psychological symptoms along with analgesia creates a risk of over usage in times of stress, in turn raising the risk of both overdose as well as a possible withdrawal-associated psychiatric crisis [121]. Barbiturate prescriptions have been on the decline for decades, but prescribers should be vigilant in monitoring patients for comorbidities as well as medication misuse.

3.5.2. Cyclobenzaprine

Cyclobenzaprine is a skeletal muscle relaxant marketed for the use of musculoskeletal pain and/or spasms, although it is also used for the treatment of fibromyalgia off-label [122]. A 2019 study that found that the association between cyclobenzaprine and suicide had an odds ratio of 1.34 (95% CI 1.06–1.68) with 7,487,505 patients. Of note, the study found a smaller risk of suicidality in men compared to women, with an odds ratio of 1.21 (0.96–1.58) vs. 1.39 (1.13–1.71), respectively [116].

3.5.3. Prednisone

Prednisone is a glucocorticoid medication used for a wide variety of pathologies. By decreasing inflammatory responses in the body, steroid medications can help with many painful rheumatic conditions. Prednisone was found to carry an overall odds ratio of suicidality of 1.33 (1.10–1.61), with higher rates in men 1.42 (1.07–1.88) vs. women 1.33 (1.08–1.64). The paper was able to study 10,667,620 patients [116]. Two commonly cited papers assessing the incident rate of psychiatric events in patients treated with steroids described a rate of severe psychiatric adverse events at 6% in patients treated at high doses, while another cohort study found an incidence of mania or depression as high as 36% among patients treated with high-dose steroid regimens [123][124].

This entry is adapted from the peer-reviewed paper 10.3390/ph16101497

References

  1. Mills, S.E.E.; Nicolson, K.P.; Smith, B.H. Chronic Pain: A Review of Its Epidemiology and Associated Factors in Population-Based Studies. Br. J. Anaesth. 2019, 123, e273–e283.
  2. Cohen, S.P.; Vase, L.; Hooten, W.M. Chronic Pain: An Update on Burden, Best Practices, and New Advances. Lancet 2021, 397, 2082–2097.
  3. GBD 2016 Disease and Injury Incidence and Prevalence Collaborators. Global, Regional, and National Incidence, Prevalence, and Years Lived with Disability for 328 Diseases and Injuries for 195 Countries, 1990–2016: A Systematic Analysis for the Global Burden of Disease Study 2016. Lancet 2017, 390, 1211–1259.
  4. Treede, R.D.; Rief, W.; Barke, A.; Aziz, Q.; Bennett, M.I.; Benoliel, R.; Cohen, M.; Evers, S.; Finnerup, N.B.; First, M.B.; et al. Chronic Pain as a Symptom or a Disease: The IASP Classification of Chronic Pain for the International Classification of Diseases (ICD-11). Pain 2019, 160, 19–27.
  5. Classification of Chronic Pain. Descriptions of Chronic Pain Syndromes and Definitions of Pain Terms. Prepared by the International Association for the Study of Pain, Subcommittee on Taxonomy. Pain Suppl. 1986, 3, S1–S226.
  6. Birkinshaw, H.; Friedrich, C.M.; Cole, P.; Eccleston, C.; Serfaty, M.; Stewart, G.; White, S.; Moore, R.A.; Phillippo, D.; Pincus, T. Antidepressants for Pain Management in Adults with Chronic Pain: A Network Meta-Analysis. Cochrane Database Syst. Rev. 2023, 5, Cd014682.
  7. Votaw, V.R.; Geyer, R.; Rieselbach, M.M.; McHugh, R.K. The Epidemiology of Benzodiazepine Misuse: A Systematic Review. Drug Alcohol. Depend. 2019, 200, 95–114.
  8. Evoy, K.E.; Sadrameli, S.; Contreras, J.; Covvey, J.R.; Peckham, A.M.; Morrison, M.D. Abuse and Misuse of Pregabalin and Gabapentin: A Systematic Review Update. Drugs 2021, 81, 125–156.
  9. Kuo, Y.F.; Liaw, V.; Yu, X.; Raji, M.A. Opioid and Benzodiazepine Substitutes: Impact on Drug Overdose Mortality in Medicare Population. Am. J. Med. 2022, 135, e194–e206.
  10. Webster, L.R. Risk Factors for Opioid-Use Disorder and Overdose. Anesth. Analg. 2017, 125, 1741–1748.
  11. Bair, M.J.; Robinson, R.L.; Katon, W.; Kroenke, K. Depression and Pain Comorbidity: A Literature Review. Arch. Intern. Med. 2003, 163, 2433–2445.
  12. Kleykamp, B.A.; Ferguson, M.C.; McNicol, E.; Bixho, I.; Arnold, L.M.; Edwards, R.R.; Fillingim, R.; Grol-Prokopczyk, H.; Turk, D.C.; Dworkin, R.H. The Prevalence of Psychiatric and Chronic Pain Comorbidities in Fibromyalgia: An ACTTION Systematic Review. Semin. Arthritis Rheum. 2021, 51, 166–174.
  13. Birgenheir, D.G.; Ilgen, M.A.; Bohnert, A.S.; Abraham, K.M.; Bowersox, N.W.; Austin, K.; Kilbourne, A.M. Pain Conditions among Veterans with Schizophrenia or Bipolar Disorder. Gen. Hosp. Psychiatry 2013, 35, 480–484.
  14. Bai, W.; Liu, Z.H.; Jiang, Y.Y.; Zhang, Q.E.; Rao, W.W.; Cheung, T.; Hall, B.J.; Xiang, Y.T. Worldwide Prevalence of Suicidal Ideation and Suicide Plan among People with Schizophrenia: A Meta-Analysis and Systematic Review of Epidemiological Surveys. Transl. Psychiatry 2021, 11, 552.
  15. Miller, J.N.; Black, D.W. Bipolar Disorder and Suicide: A Review. Curr. Psychiatry Rep. 2020, 22, 6.
  16. van Draanen, J.; Tsang, C.; Mitra, S.; Phuong, V.; Murakami, A.; Karamouzian, M.; Richardson, L. Mental Disorder and Opioid Overdose: A Systematic Review. Soc. Psychiatry Psychiatr. Epidemiol. 2022, 57, 647–671.
  17. Koller, G.; Schwarzer, A.; Halfter, K.; Soyka, M. Pain Management in Opioid Maintenance Treatment. Expert. Opin. Pharmacother. 2019, 20, 1993–2005.
  18. O’Brien, C.P. Benzodiazepine Use, Abuse, and Dependence. J. Clin. Psychiatry 2005, 66 (Suppl. S2), 28–33.
  19. Argoff, C.E.; Alford, D.P.; Fudin, J.; Adler, J.A.; Bair, M.J.; Dart, R.C.; Gandolfi, R.; McCarberg, B.H.; Stanos, S.P.; Gudin, J.A.; et al. Rational Urine Drug Monitoring in Patients Receiving Opioids for Chronic Pain: Consensus Recommendations. Pain Med. 2018, 19, 97–117.
  20. Manchikanti, L.; Malla, Y.; Wargo, B.W.; Fellows, B. Comparative Evaluation of the Accuracy of Immunoassay with Liquid Chromatography Tandem Mass Spectrometry (LC/MS/MS) of Urine Drug Testing (UDT) Opioids and Illicit Drugs in Chronic Pain Patients. Pain Physician 2011, 14, 175–187.
  21. Snyder, M.L.; Fantz, C.R.; Melanson, S. Immunoassay-Based Drug Tests Are Inadequately Sensitive for Medication Compliance Monitoring in Patients Treated for Chronic Pain. Pain Physician 2017, 20, SE1–SE9.
  22. Darragh, A.; Snyder, M.L.; Ptolemy, A.S.; Melanson, S. KIMS, CEDIA, and HS-CEDIA Immunoassays Are Inadequately Sensitive for Detection of Benzodiazepines in Urine from Patients Treated for Chronic Pain. Pain Physician 2014, 17, 359–366.
  23. Smith, B.H.; Macfarlane, G.J.; Torrance, N. Epidemiology of Chronic Pain, from the Laboratory to the Bus Stop: Time to Add Understanding of Biological Mechanisms to the Study of Risk Factors in Population-Based Research? Pain 2007, 127, 5–10.
  24. Dahlhamer, J. Prevalence of Chronic Pain and High-Impact Chronic Pain Among Adults—United States, 2016. MMWR Morb. Mortal. Wkly. Rep. 2018, 67.
  25. Jackson, T.; Thomas, S.; Stabile, V.; Shotwell, M.; Han, X.; McQueen, K. A Systematic Review and Meta-Analysis of the Global Burden of Chronic Pain Without Clear Etiology in Low- and Middle-Income Countries: Trends in Heterogeneous Data and a Proposal for New Assessment Methods. Anesth. Analg. 2016, 123, 739–748.
  26. Domenichiello, A.F.; Ramsden, C.E. The Silent Epidemic of Chronic Pain in Older Adults. Prog. Neuropsychopharmacol. Biol. Psychiatry 2019, 93, 284–290.
  27. Pitcher, M.H.; Korff, M.V.; Bushnell, M.C.; Porter, L. Prevalence and Profile of High-Impact Chronic Pain in the United States. J. Pain 2019, 20, 146–160.
  28. Greenspan, J.D.; Craft, R.M.; LeResche, L.; Arendt-Nielsen, L.; Berkley, K.J.; Fillingim, R.B.; Gold, M.S.; Holdcroft, A.; Lautenbacher, S.; Mayer, E.A.; et al. Studying Sex and Gender Differences in Pain and Analgesia: A Consensus Report. Pain 2007, 132, S26–S45.
  29. Ferreira, K.d.S.; Speciali, J.G. Epidemiology of Chronic Pain in the Office of a Pain Specialist Neurologist. Arq. Neuropsiquiatr. 2015, 73, 582–585.
  30. El-Shormilisy, N.; Strong, J.; Meredith, P.J. Associations between Gender, Coping Patterns and Functioning for Individuals with Chronic Pain: A Systematic Review. Pain Res. Manag. 2015, 20, 48–55.
  31. Vieira, E.B.d.M.; Garcia, J.B.S.; da Silva, A.A.M.; Araújo, R.L.T.M.; Jansen, R.C.S.; Bertrand, A.L.X. Chronic Pain, Associated Factors, and Impact on Daily Life: Are There Differences between the Sexes? Cad. Saude Publica 2012, 28, 1459–1467.
  32. Guerriere, D.N.; Choinière, M.; Dion, D.; Peng, P.; Stafford-Coyte, E.; Zagorski, B.; Banner, R.; Barton, P.M.; Boulanger, A.; Clark, A.J.; et al. The Canadian STOP-PAIN Project—Part 2: What Is the Cost of Pain for Patients on Waitlists of Multidisciplinary Pain Treatment Facilities? Can. J. Anesth./J. Can. D’anesthésie 2010, 57, 549–558.
  33. Janevic, M.R.; McLaughlin, S.J.; Heapy, A.A.; Thacker, C.; Piette, J.D. Racial and Socioeconomic Disparities in Disabling Chronic Pain: Findings From the Health and Retirement Study. J. Pain 2017, 18, 1459–1467.
  34. Tang, N.K.Y.; Crane, C. Suicidality in Chronic Pain: A Review of the Prevalence, Risk Factors and Psychological Links. Psychol. Med. 2006, 36, 575–586.
  35. Stenager, E.; Stenager, E. . Ugeskr. Laeger 2008, 170, 517–522.
  36. Timonen, M.; Viilo, K.; Hakko, H.; Särkioja, T.; Ylikulju, M.; Meyer-Rochow, V.B.; Väisänen, E.; Räsänen, P. Suicides in Persons Suffering from Rheumatoid Arthritis. Rheumatology 2003, 42, 287–291.
  37. Cheng, A.T.; Chen, T.H.; Chen, C.C.; Jenkins, R. Psychosocial and Psychiatric Risk Factors for Suicide. Case-Control Psychological Autopsy Study. Br. J. Psychiatry 2000, 177, 360–365.
  38. Morasco, B.J.; Gritzner, S.; Lewis, L.; Oldham, R.; Turk, D.C.; Dobscha, S.K. Systematic Review of Prevalence, Correlates, and Treatment Outcomes for Chronic Non-Cancer Pain in Patients with Comorbid Substance Use Disorder. Pain 2011, 152, 488–497.
  39. Fishbain, D.A.; Cole, B.; Lewis, J.; Rosomoff, H.L.; Rosomoff, R.S. What Percentage of Chronic Nonmalignant Pain Patients Exposed to Chronic Opioid Analgesic Therapy Develop Abuse/Addiction and/or Aberrant Drug-Related Behaviors? A Structured Evidence-Based Review. Pain Med. 2008, 9, 444–459.
  40. Tegethoff, M.; Belardi, A.; Stalujanis, E.; Meinlschmidt, G. Comorbidity of Mental Disorders and Chronic Pain: Chronology of Onset in Adolescents of a National Representative Cohort. J. Pain 2015, 16, 1054–1064.
  41. Lagerberg, T.; Molero, Y.; D’Onofrio, B.M.; Fernández de la Cruz, L.; Lichtenstein, P.; Mataix-Cols, D.; Rück, C.; Hellner, C.; Chang, Z. Antidepressant Prescription Patterns and CNS Polypharmacy with Antidepressants among Children, Adolescents, and Young Adults: A Population-Based Study in Sweden. Eur. Child Adolesc. Psychiatry 2019, 28, 1137–1145.
  42. Bachmann, C.J.; Aagaard, L.; Burcu, M.; Glaeske, G.; Kalverdijk, L.J.; Petersen, I.; Schuiling-Veninga, C.C.M.; Wijlaars, L.; Zito, J.M.; Hoffmann, F. Trends and Patterns of Antidepressant Use in Children and Adolescents from Five Western Countries, 2005–2012. Eur. Neuropsychopharmacol. 2016, 26, 411–419.
  43. Welsch, P.; Üçeyler, N.; Klose, P.; Walitt, B.; Häuser, W. Serotonin and Noradrenaline Reuptake Inhibitors (SNRIs) for Fibromyalgia. Cochrane Database Syst. Rev. 2018, 2, CD010292.
  44. Szok, D.; Tajti, J.; Nyári, A.; Vécsei, L. Therapeutic Approaches for Peripheral and Central Neuropathic Pain. Behav. Neurol. 2019, 2019, 8685954.
  45. Schwan, J.; Sclafani, J.; Tawfik, V.L. Chronic Pain Management in the Elderly. Anesthesiol. Clin. 2019, 37, 547–560.
  46. Khawam, E.A.; Laurencic, G.; Malone, D.A. Side Effects of Antidepressants: An Overview. Cleve Clin. J. Med. 2006, 73, 351–353, 356–361.
  47. Newton-John, T.R.O. Negotiating the Maze: Risk Factors for Suicidal Behavior in Chronic Pain Patients. Curr. Pain. Headache Rep. 2014, 18, 447.
  48. Wilson, K.G.; Kowal, J.; Henderson, P.R.; McWilliams, L.A.; Péloquin, K. Chronic Pain and the Interpersonal Theory of Suicide. Rehabil. Psychol. 2013, 58, 111–115.
  49. Hooley, J.M.; Franklin, J.C.; Nock, M.K. Chronic Pain and Suicide: Understanding the Association. Curr. Pain Headache Rep. 2014, 18, 435.
  50. Zalsman, G.; Hawton, K.; Wasserman, D.; van Heeringen, K.; Arensman, E.; Sarchiapone, M.; Carli, V.; Höschl, C.; Barzilay, R.; Balazs, J.; et al. Suicide Prevention Strategies Revisited: 10-Year Systematic Review. Lancet Psychiatry 2016, 3, 646–659.
  51. Amendola, S.; Plöderl, M.; Hengartner, M.P. Did the Introduction and Increased Prescribing of Antidepressants Lead to Changes in Long-Term Trends of Suicide Rates? Eur. J. Public Health 2021, 31, 291–297.
  52. Kamat, M.A.; Edgar, L.; Niblock, P.; McDowell, C.; Kelly, C.B. Association between Antidepressant Prescribing and Suicide Rates in OECD Countries: An Ecological Study. Pharmacopsychiatry 2014, 47, 18–21.
  53. Safer, D.J.; Zito, J.M. Do Antidepressants Reduce Suicide Rates? Public Health 2007, 121, 274–277.
  54. Aursnes, I.; Tvete, I.F.; Gaasemyr, J.; Natvig, B. Even More Suicide Attempts in Clinical Trials with Paroxetine Randomised against Placebo. BMC Psychiatry 2006, 6, 55.
  55. Fergusson, D.; Doucette, S.; Glass, K.C.; Shapiro, S.; Healy, D.; Hebert, P.; Hutton, B. Association between Suicide Attempts and Selective Serotonin Reuptake Inhibitors: Systematic Review of Randomised Controlled Trials. BMJ 2005, 330, 396.
  56. Hengartner, M.P.; Plöderl, M. Newer-Generation Antidepressants and Suicide Risk in Randomized Controlled Trials: A Re-Analysis of the FDA Database. Psychother. Psychosom. 2019, 88, 247–248.
  57. Plöderl, M.; Hengartner, M.P.; Bschor, T.; Kaminski, J.A. Commentary to “Antidepressants and Suicidality: A Re-Analysis of the Re-Analysis”. J. Affect. Disord. 2020, 273, 252–253.
  58. Jakobsen, J.C.; Katakam, K.K.; Schou, A.; Hellmuth, S.G.; Stallknecht, S.E.; Leth-Møller, K.; Iversen, M.; Banke, M.B.; Petersen, I.J.; Klingenberg, S.L.; et al. Selective Serotonin Reuptake Inhibitors versus Placebo in Patients with Major Depressive Disorder. A Systematic Review with Meta-Analysis and Trial Sequential Analysis. BMC Psychiatry 2017, 17, 58.
  59. Sharma, T.; Guski, L.S.; Freund, N.; Gøtzsche, P.C. Suicidality and Aggression during Antidepressant Treatment: Systematic Review and Meta-Analyses Based on Clinical Study Reports. BMJ 2016, 352, i65.
  60. Stone, M.; Laughren, T.; Jones, M.L.; Levenson, M.; Holland, P.C.; Hughes, A.; Hammad, T.A.; Temple, R.; Rochester, G. Risk of Suicidality in Clinical Trials of Antidepressants in Adults: Analysis of Proprietary Data Submitted to US Food and Drug Administration. BMJ 2009, 339, b2880.
  61. Li, K.; Zhou, G.; Xiao, Y.; Gu, J.; Chen, Q.; Xie, S.; Wu, J. Risk of Suicidal Behaviors and Antidepressant Exposure Among Children and Adolescents: A Meta-Analysis of Observational Studies. Front. Psychiatry 2022, 13, 880496.
  62. Nobile, B.; Ramoz, N.; Jaussent, I.; Dubois, J.; Guillaume, S.; Gorwood, P.; Courtet, P. Polymorphisms of Stress Pathway Genes and Emergence of Suicidal Ideation at Antidepressant Treatment Onset. Transl. Psychiatry 2020, 10, 320.
  63. Menke, A.; Domschke, K.; Czamara, D.; Klengel, T.; Hennings, J.; Lucae, S.; Baune, B.T.; Arolt, V.; Müller-Myhsok, B.; Holsboer, F.; et al. Genome-Wide Association Study of Antidepressant Treatment-Emergent Suicidal Ideation. Neuropsychopharmacology 2012, 37, 797–807.
  64. Voegeli, G.; Ramoz, N.; Shekhtman, T.; Courtet, P.; Gorwood, P.; Kelsoe, J.R. Neurotrophin Genes and Antidepressant-Worsening Suicidal Ideation: A Prospective Case-Control Study. Int. J. Neuropsychopharmacol. 2016, 19, pyw059.
  65. Perroud, N.; Aitchison, K.J.; Uher, R.; Smith, R.; Huezo-Diaz, P.; Marusic, A.; Maier, W.; Mors, O.; Placentino, A.; Henigsberg, N.; et al. Genetic Predictors of Increase in Suicidal Ideation during Antidepressant Treatment in the GENDEP Project. Neuropsychopharmacology 2009, 34, 2517–2528.
  66. Björkenstam, C.; Möller, J.; Ringbäck, G.; Salmi, P.; Hallqvist, J.; Ljung, R. An Association between Initiation of Selective Serotonin Reuptake Inhibitors and Suicide—A Nationwide Register-Based Case-Crossover Study. PLoS ONE 2013, 8, e73973.
  67. Christiansen, E.; Agerbo, E.; Bilenberg, N.; Stenager, E. SSRIs and Risk of Suicide Attempts in Young People—A Danish Observational Register-Based Historical Cohort Study, Using Propensity Score. Nord. J. Psychiatry 2016, 70, 167–175.
  68. Case, A.; Deaton, A. Rising Morbidity and Mortality in Midlife among White Non-Hispanic Americans in the 21st Century. Proc. Natl. Acad. Sci. USA 2015, 112, 15078–15083.
  69. Scherrer, J.F.; Svrakic, D.M.; Freedland, K.E.; Chrusciel, T.; Balasubramanian, S.; Bucholz, K.K.; Lawler, E.V.; Lustman, P.J. Prescription Opioid Analgesics Increase the Risk of Depression. J. Gen. Intern. Med. 2014, 29, 491–499.
  70. Scherrer, J.F.; Salas, J.; Copeland, L.A.; Stock, E.M.; Ahmedani, B.K.; Sullivan, M.D.; Burroughs, T.; Schneider, F.D.; Bucholz, K.K.; Lustman, P.J. Prescription Opioid Duration, Dose, and Increased Risk of Depression in 3 Large Patient Populations. Ann. Fam. Med. 2016, 14, 54–62.
  71. Products—Vital Statistics Rapid Release—Provisional Drug Overdose Data. Available online: https://www.cdc.gov/nchs/nvss/vsrr/drug-overdose-data.htm (accessed on 26 August 2023).
  72. U.S. Opioid Dispensing Rate Maps|Drug Overdose|CDC Injury Center. Available online: https://www.cdc.gov/drugoverdose/rxrate-maps/index.html (accessed on 26 August 2023).
  73. Yang, T.-C.; Kim, S.; Shoff, C. Income Inequality and Opioid Prescribing Rates: Exploring Rural/Urban Differences in Pathways via Residential Stability and Social Isolation. Rural. Sociol. 2021, 86, 26–49.
  74. HONG, J.; KNAPP, M.; McGUIRE, A. Income-Related Inequalities in the Prevalence of Depression and Suicidal Behaviour: A 10-Year Trend Following Economic Crisis. World Psychiatry 2011, 10, 40–44.
  75. Barber, C.W.; Miller, M.J. Reducing a Suicidal Person’s Access to Lethal Means of Suicide: A Research Agenda. Am. J. Prev. Med. 2014, 47, S264–S272.
  76. Miller, T.R.; Swedler, D.I.; Lawrence, B.A.; Ali, B.; Rockett, I.R.H.; Carlson, N.N.; Leonardo, J. Incidence and Lethality of Suicidal Overdoses by Drug Class. JAMA Netw. Open 2020, 3, e200607.
  77. Back, S.E.; Payne, R.L.; Wahlquist, A.H.; Carter, R.E.; Stroud, Z.; Haynes, L.; Hillhouse, M.; Brady, K.T.; Ling, W. Comparative Profiles of Men and Women with Opioid Dependence: Results from a National Multisite Effectiveness Trial. Am. J. Drug Alcohol. Abuse 2011, 37, 313–323.
  78. McHugh, R.K.; Devito, E.E.; Dodd, D.; Carroll, K.M.; Potter, J.S.; Greenfield, S.F.; Connery, H.S.; Weiss, R.D. Gender Differences in a Clinical Trial for Prescription Opioid Dependence. J. Subst. Abus. Treat. 2013, 45, 38–43.
  79. Han, B.; Compton, W.M.; Einstein, E.B.; Cotto, J.; Hobin, J.A.; Stein, J.B.; Volkow, N.D. Intentional Drug Overdose Deaths in the United States. AJP 2022, 179, 163–165.
  80. Alang, S.M. Mental Health Care among Blacks in America: Confronting Racism and Constructing Solutions. Health Serv. Res. 2019, 54, 346–355.
  81. Jankovic, J.; Parsons, J.; Jovanović, N.; Berrisford, G.; Copello, A.; Fazil, Q.; Priebe, S. Differences in Access and Utilisation of Mental Health Services in the Perinatal Period for Women from Ethnic Minorities—A Population-Based Study. BMC Med. 2020, 18, 245.
  82. Cook, B.L.; Trinh, N.-H.; Li, Z.; Hou, S.S.-Y.; Progovac, A.M. Trends in Racial-Ethnic Disparities in Access to Mental Health Care, 2004–2012. Psychiatr. Serv. 2017, 68, 9–16.
  83. Khan, M.R.; Hoff, L.; Elliott, L.; Scheidell, J.D.; Pamplin, J.R.; Townsend, T.N.; Irvine, N.M.; Bennett, A.S. Racial/Ethnic Disparities in Opioid Overdose Prevention: Comparison of the Naloxone Care Cascade in White, Latinx, and Black People Who Use Opioids in New York City. Harm Reduct. J. 2023, 20, 24.
  84. Derry, S.; Bell, R.F.; Straube, S.; Wiffen, P.J.; Aldington, D.; Moore, R.A. Pregabalin for Neuropathic Pain in Adults. Cochrane Database Syst. Rev. 2019, 1, Cd007076.
  85. Wiffen, P.J.; Derry, S.; Bell, R.F.; Rice, A.S.; Tölle, T.R.; Phillips, T.; Moore, R.A. Gabapentin for Chronic Neuropathic Pain in Adults. Cochrane Database Syst. Rev. 2017, 6, Cd007938.
  86. Goodman, C.W.; Brett, A.S. Gabapentin and Pregabalin for Pain—Is Increased Prescribing a Cause for Concern? N. Engl. J. Med. 2017, 377, 411–414.
  87. Bailly, F.; Belaid, H. Suicidal Ideation and Suicide Attempt Associated with Antidepressant and Antiepileptic Drugs: Implications for Treatment of Chronic Pain. Jt. Bone Spine 2021, 88, 105005.
  88. Peckham, A.M.; Ananickal, M.J.; Sclar, D.A. Gabapentin Use, Abuse, and the US Opioid Epidemic: The Case for Reclassification as a Controlled Substance and the Need for Pharmacovigilance. Risk Manag. Healthc. Policy 2018, 11, 109–116.
  89. Guy, G.P.; Zhang, K.; Bohm, M.K.; Losby, J.; Lewis, B.; Young, R.; Murphy, L.B.; Dowell, D. Vital Signs: Changes in Opioid Prescribing in the United States, 2006-2015. MMWR Morb. Mortal. Wkly. Rep. 2017, 66, 697–704.
  90. Paulozzi, L.J.; Mack, K.A.; Hockenberry, J.M. Division of Unintentional Injury Prevention, National Center for Injury Prevention and Control, CDC Vital Signs: Variation among States in Prescribing of Opioid Pain Relievers and Benzodiazepines—United States, 2012. MMWR Morb. Mortal. Wkly. Rep. 2014, 63, 563–568.
  91. Park, T.W.; Saitz, R.; Nelson, K.P.; Xuan, Z.; Liebschutz, J.M.; Lasser, K.E. The Association between Benzodiazepine Prescription and Aberrant Drug-Related Behaviors in Primary Care Patients Receiving Opioids for Chronic Pain. Subst. Abus. 2016, 37, 516–520.
  92. Dasgupta, N.; Funk, M.J.; Proescholdbell, S.; Hirsch, A.; Ribisl, K.M.; Marshall, S. Cohort Study of the Impact of High-Dose Opioid Analgesics on Overdose Mortality. Pain. Med. 2016, 17, 85–98.
  93. Chen, L.H.; Hedegaard, H.; Warner, M. Drug-Poisoning Deaths Involving Opioid Analgesics: United States, 1999–2011; NCHS Data Brief; National Institute of Health: Stapleton, NY, USA, 2014; pp. 1–8.
  94. Turner, B.J.; Liang, Y. Drug Overdose in a Retrospective Cohort with Non-Cancer Pain Treated with Opioids, Antidepressants, and/or Sedative-Hypnotics: Interactions with Mental Health Disorders. J. Gen. Intern. Med. 2015, 30, 1081–1096.
  95. Park, T.W.; Saitz, R.; Ganoczy, D.; Ilgen, M.A.; Bohnert, A.S.B. Benzodiazepine Prescribing Patterns and Deaths from Drug Overdose among US Veterans Receiving Opioid Analgesics: Case-Cohort Study. BMJ 2015, 350, h2698.
  96. Sun, E.C.; Dixit, A.; Humphreys, K.; Darnall, B.D.; Baker, L.C.; Mackey, S. Association between Concurrent Use of Prescription Opioids and Benzodiazepines and Overdose: Retrospective Analysis. BMJ 2017, 356, j760.
  97. Nielsen, S.; Lintzeris, N.; Bruno, R.; Campbell, G.; Larance, B.; Hall, W.; Hoban, B.; Cohen, M.L.; Degenhardt, L. Benzodiazepine Use among Chronic Pain Patients Prescribed Opioids: Associations with Pain, Physical and Mental Health, and Health Service Utilization. Pain Med. 2015, 16, 356–366.
  98. Day, C. Benzodiazepines in Combination with Opioid Pain Relievers or Alcohol: Greater Risk of More Serious ED Visit Outcomes. In The CBHSQ Report; Substance Abuse and Mental Health Services Administration (US): Rockville, MD, USA, 2013.
  99. Yarborough, B.J.H.; Stumbo, S.P.; Stoneburner, A.; Smith, N.; Dobscha, S.K.; Deyo, R.A.; Morasco, B.J. Correlates of Benzodiazepine Use and Adverse Outcomes Among Patients with Chronic Pain Prescribed Long-Term Opioid Therapy. Pain Med. 2019, 20, 1148–1155.
  100. Fawcett, J. Treating Impulsivity and Anxiety in the Suicidal Patient. Ann. N. Y. Acad. Sci. 2001, 932, 94–102, discussion 102–105.
  101. Malik, S.; Kanwar, A.; Sim, L.A.; Prokop, L.J.; Wang, Z.; Benkhadra, K.; Murad, M.H. The Association between Sleep Disturbances and Suicidal Behaviors in Patients with Psychiatric Diagnoses: A Systematic Review and Meta-Analysis. Syst. Rev. 2014, 3, 18.
  102. Ahlm, K.; Saveman, B.-I.; Björnstig, U. Drowning Deaths in Sweden with Emphasis on the Presence of Alcohol and Drugs—A Retrospective Study, 1992-2009. BMC Public Health 2013, 13, 216.
  103. Darke, S.; Deady, M.; Duflou, J. Toxicology and Characteristics of Deaths Involving Zolpidem in New South Wales, Australia 2001-2010. J. Forensic Sci. 2012, 57, 1259–1262.
  104. Shih, H.-I.; Lin, M.-C.; Lin, C.-C.; Hsu, H.-C.; Lee, H.-L.; Chi, C.-H.; Sung, F.-C.; Chang, Y.-J.; Kao, C.-H. Benzodiazepine Therapy in Psychiatric Outpatients Is Associated with Deliberate Self-Poisoning Events at Emergency Departments-a Population-Based Nested Case-Control Study. Psychopharmacology 2013, 229, 665–671.
  105. Dodds, T.J. Prescribed Benzodiazepines and Suicide Risk: A Review of the Literature. Prim. Care Companion CNS Disord. 2017, 19, 16r02037.
  106. Brower, K.J.; McCammon, R.J.; Wojnar, M.; Ilgen, M.A.; Wojnar, J.; Valenstein, M. Prescription Sleeping Pills, Insomnia, and Suicidality in the National Comorbidity Survey Replication. J. Clin. Psychiatry 2011, 72, 515–521.
  107. Lecat, N.; Fourrier-Réglat, A.; Montagni, I.; Tzourio, C.; Pariente, A.; Verdoux, H.; Tournier, M. Association between Anxiolytic/Hypnotic Drugs and Suicidal Thoughts or Behaviors in a Population-Based Cohort of Students. Psychiatry Res. 2020, 291, 113276.
  108. Tiihonen, J.; Mittendorfer-Rutz, E.; Torniainen, M.; Alexanderson, K.; Tanskanen, A. Mortality and Cumulative Exposure to Antipsychotics, Antidepressants, and Benzodiazepines in Patients With Schizophrenia: An Observational Follow-Up Study. Am. J. Psychiatry 2016, 173, 600–606.
  109. Tiihonen, J.; Suokas, J.T.; Suvisaari, J.M.; Haukka, J.; Korhonen, P. Polypharmacy with Antipsychotics, Antidepressants, or Benzodiazepines and Mortality in Schizophrenia. Arch. Gen. Psychiatry 2012, 69, 476–483.
  110. Cato, V.; Holländare, F.; Nordenskjöld, A.; Sellin, T. Association between Benzodiazepines and Suicide Risk: A Matched Case-Control Study. BMC Psychiatry 2019, 19, 317.
  111. Albrecht, B.; Staiger, P.K.; Hall, K.; Miller, P.; Best, D.; Lubman, D.I. Benzodiazepine Use and Aggressive Behaviour: A Systematic Review. Aust. N. Z. J. Psychiatry 2014, 48, 1096–1114.
  112. Gvion, Y.; Apter, A. Aggression, Impulsivity, and Suicide Behavior: A Review of the Literature. Arch. Suicide Res. 2011, 15, 93–112.
  113. Sun, Y.; Lin, C.-C.; Lu, C.-J.; Hsu, C.-Y.; Kao, C.-H. Association Between Zolpidem and Suicide: A Nationwide Population-Based Case-Control Study. Mayo Clin. Proc. 2016, 91, 308–315.
  114. Cho, C.-H.; Jee, H.-J.; Nam, Y.-J.; An, H.; Kim, L.; Lee, H.-J. Temporal Association between Zolpidem Medication and the Risk of Suicide: A 12-Year Population-Based, Retrospective Cohort Study. Sci. Rep. 2020, 10, 4875.
  115. Millea, P.J.; Brodie, J.J. Tension-Type Headache. Am. Fam. Physician 2002, 66, 797–805.
  116. Gibbons, R. Medications and Suicide: High Dimensional Empirical Bayes Screening (iDEAS). Harv. Data Sci. Rev. 2019, 1.
  117. Stovner, L.J.; Hagen, K.; Linde, M.; Steiner, T.J. The Global Prevalence of Headache: An Update, with Analysis of the Influences of Methodological Factors on Prevalence Estimates. J. Headache Pain 2022, 23, 34.
  118. Lyngberg, A.C.; Rasmussen, B.K.; Jørgensen, T.; Jensen, R. Has the Prevalence of Migraine and Tension-Type Headache Changed over a 12-Year Period? A Danish Population Survey. Eur. J. Epidemiol. 2005, 20, 243–249.
  119. Friedman, A.P.; DiSerio, F.J. Symptomatic Treatment of Chronically Recurring Tension Headache: A Placebo-Controlled, Multicenter Investigation of Fioricet and Acetaminophen with Codeine. Clin. Ther. 1987, 10, 69–81.
  120. Lake III, A.E.; Rains, J.C.; Penzien, D.B.; Lipchik, G.L. Headache and Psychiatric Comorbidity: Historical Context, Clinical Implications, and Research Relevance. Headache J. Head Face Pain 2005, 45, 493–506.
  121. Evans, R.W.; Baskin, S.M. Why Do Migraineurs Abuse Butalbital-Containing Combination Analgesics? Headache J. Head Face Pain 2010, 50, 1194–1197.
  122. Macfarlane, G.J.; Kronisch, C.; Dean, L.E.; Atzeni, F.; Häuser, W.; Fluß, E.; Choy, E.; Kosek, E.; Amris, K.; Branco, J.; et al. EULAR Revised Recommendations for the Management of Fibromyalgia. Ann. Rheum. Dis. 2017, 76, 318–328.
  123. Lewis, D.A.; Smith, R.E. Steroid-Induced Psychiatric Syndromes. A Report of 14 Cases and a Review of the Literature. J. Affect. Disord. 1983, 5, 319–332.
  124. Naber, D.; Sand, P.; Heigl, B. Psychopathological and Neuropsychological Effects of 8-Days’ Corticosteroid Treatment. A Prospective Study. Psychoneuroendocrinology 1996, 21, 25–31.
More
© Text is available under the terms and conditions of the Creative Commons Attribution (CC BY) license; additional terms may apply. By using this site, you agree to the Terms and Conditions and Privacy Policy.
This entry is offline, you can click here to edit this entry!
Video Production Service
Feedback